

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

Mouse PAR34 mature VH amino acid sequence (SEQ ID NO:2)

E I Q L Q Q S G P E L V K P G A S V K V
S C K A S G Y A F T N Y N M Y W V K Q S
H G K S L E W I G Y I D P Y Y G D P G Y
S Q K F K G K A T L T V D K S S S T A Y
M H L N S L T S E D S A V Y Y C A R R G
N F P Y Y F D Y W G Q G T T L T V S S

Mouse PAR34 mature VL amino acid sequence (SEQ ID NO:3)

D I K M T Q S P S S M Y A S L G E R V T
I T C K A S Q D I N S Y L S W F Q Q K P
G K S P K T L I Y R A N R L V D G V P S
R F S G S G S G Q D Y S L T I S S L E Y
E D M G I Y Y C L Q Y D E F P Y T F G G
G T K L E I K

Mouse PAR80 mature VH Region Amino Acid Sequence (SEQ ID NO:4)

E V Q L Q Q S G A E L V R S G A S V K L
S C T A S G F N I K D Y Y I H W V K Q R
P E Q G L E W I G C I D P E N G D T E Y
A P N F Q G R A T M T A D T S S N T A Y
L Q L S S L T S E D T A V Y Y C Y G G T
I T F A Y W G Q G T L V T V S A

Mouse PAR80 mature VL Region Amino Acid Sequence (SEQ ID NO: 5)

Q A V V T Q E S A L T T S P G E T V T L
T C R S S T G A V T T S N S A N W V Q E
K P D H L F T G L I G G T I N R V P G V
P A R F S G S L I G D K A A L T I T G A
Q T E D E A I Y F C A L W Y S N H W V F
G G G T K L T V L G

The CDRs based on the definition of Kabat are bolded and underlined.

FIG. 1

Panel of Monoclonal Antibodies Generated Against Human AR

ANTI-BODY	ISO-TYPE	BINDING						INHIBITION OF AR-EGFR INTER-ACTION	INHIBITION OF AR-MEDIATED PROLIFERATION (µg/ml)			
		AR	Surface AR	EGF	HB EGF	Cyno AR	Murine AR		3T3		HEKn	
									IC50%	IC90%	IC50%	IC90%
PAR2	IgG1, λ	+++	+++	-	-	+++	+++	++	0.13	1.3	0.35	>3
PAR 5	IgG1, λ	+++	+++	-	-	ND	+++	++	0.8	7.2	ND	ND
PAR15	IgG1, λ	+++	++	-	-	+++	+++	++	0.11	0.71	.2	>3
PAR19	IgG2b, κ	+++	+++	-	-	ND	-	++	5.9	>10	ND	ND
PAR22	IgG1, λ	+++	++	-	-	ND	+++	++	6.8	>10	ND	ND
PAR23	IgG1, λ	+++	++	-	-	ND	++	++	1.7	6.9	ND	ND
PAR26	IgG2b, κ	+++	+++	-	-	ND	-	++	>10	>10	>3	>3
PAR29	IgG1, λ	+++	+++	-	-	ND	+++	++	0.9	>10	ND	ND
PAR31	IgG2b, λ	+++	+++	-	-	+++	+++	++	0.7	1.9	.07	>3
PAR34	IgG2b, κ	+++	+++	-	-	+++	+++	++	0.072	0.71	.041	2.95
PAR44	IgG1, κ	+++	++	-	-	ND	+++	ND	4.1	>10	1.7	>3
PAR46	IgG1, κ	+++	++	-	-	ND	+++	ND	0.6	>10	ND	ND
PAR51	IgG1, λ	+++	++	-	-	ND	++	ND	4	>10	ND	ND
PAR67	IgG2b, κ	+++	++	-	-	+++	-	ND	>10	>10	>3	>3
PAR79	IgG1, κ	+++	++	-	-	ND	-	ND	2.8	>10	ND	ND
PAR80	IgG2a, λ	+++	+++	-	-	+++	-	ND	0.072	0.42	0.2	2.8
PAR81	IgG1, κ	+++	++	-	-	ND	-	ND	3.9	>10	ND	ND
PAR84	IgG2a, λ	+++	+++	-	-	+++	-	ND	0.51	0.8	0.48	>3

BINDING – direct binding as detected by ELISA

INHIBITION OF AR-EGFR INTERACTION – ability to inhibit AR binding to A431 (human EGFR+ epidermoid carcinoma)

INHIBITION OF PROLIFERATION – inhibition of proliferation of 3T3 (murine) cells to 100 ng exogenous human AR, or HEKn (human) cells to endogenously produced AR

ND – not determined; IC50% is the amount of the antibody needed to accomplish 50% inhibition; IC90% is the amount of the antibody needed to accomplish 90% inhibition

FIG. 2




FIG. 3





FIG. 4




FIG. 5




FIG. 6




FIG. 7

cDNA (SEQ ID NO:8) and amino acid (SEQ ID NO:9) sequences for the signal peptide and heavy chain variable region of the PAR34 antibody.

```

                                     30                               60
ATGGAATGGAGATGGATCTTTCTCTTCCTGTCAGGAACTACAGGTGTCCACTCTGAG
M E W R W I F L F L L S G T T G V H S E

                                     90                               120
ATCCAGCTGCAGCAGTCTGGACCTGAGCTGGTGAAGCCTGGGGCTTCAGTGAAGGTATCC
I Q L Q Q S G P E L V K P G A S V K V S

                                     150                               180
TGCAAGGCTTCTGGTTATGCATTCACTAACTACAACATGTACTGGGTGAAGCAGAGCCAT
C K A S G Y A F T N Y N M Y W V K Q S H

                                     210                               240
GGAAAGAGCCTTGAGTGGATTGGATATATTGATCCTTACTATGGTGATCCTGGCTACAGC
G K S L E W I G Y I D P Y Y G D P G Y S

                                     270                               300
CAGAAGTTCAAGGGCAAGGCCACATTGACTGTTGACAAGTCCTCCAGCACAGCCTACATG
Q K F K G K A T L T V D K S S S T A Y M

                                     330                               360
CATCTCAACAGCCTGACATCTGAGGACTCTGCAGTCTATTACTGTGCAAGACGGGGTAAC
H L N S L T S E D S A V Y Y C A R R G N

                                     390                               414
TTCCCGTACTACTTTGACTACTGGGGCCAAGGCACCACTCTCACAGTCTCCTCA
F P Y Y F D Y W G Q G T T L T V S S
```

FIG. 8

cDNA (SEQ ID NO:10) and amino acid (SEQ ID NO:11) sequences for the signal peptide and light chain variable region of the PAR34 antibody.

```

                                     30                                     60
ATGAGGACCCCTGCTCAGTTTCTTGGAATCTTGTTGCTCTGGTTTCCAGGTATCAAATGT
M R T P A Q F L G I L L L W F P G I K C

                                     90                                     120
GACATCAAGATGACCCAGTCTCCATCTTCCATGTATGCATCTCTAGGAGAGAGAGTCACT
D I K M T Q S P S S M Y A S L G E R V T

                                     150                                     180
ATCACTTGCAAGGCGAGTCAGGACATTAATAGCTATTTAAGCTGGTTCCAGCAGAAACCA
I T C K A S Q D I N S Y L S W F Q Q K P

                                     210                                     240
GGGAAATCTCCTAAGACCCTGATCTATCGTGCAAACAGATTGGTAGATGGGGTCCCATCA
G K S P K T L I Y R A N R L V D G V P S

                                     270                                     300
AGGTTCAGTGGCAGTGGATCTGGGCAAGATTATTCTCTCACCATCAGCAGCCTGGAGTAT
R F S G S G S G Q D Y S L T I S S L E Y

                                     330                                     360
GAAGATATGGGAATTTATTATTGTCTACAGTATGATGAGTTTCCGTACACGTTTCGGAGGG
E D M G I Y Y C L Q Y D E F P Y T F G G

                                     381
GGGACCAAGCTGGAAATAAAA
G T K L E I K
```

FIG. 9

Alignment of the VH region amino acid sequences of PAR34 (SEQ ID NO:2), HuPAR34 (SEQ ID NO:12), and the human germline DP-3/JH4 segments (SEQ ID NO:13).

		30
PAR34	E I Q L Q Q S G P E L V K P G A S V K V S C K A S G Y A F T	
HuPAR34	E V Q L V Q S G A E V K K P G A <u>S</u> V K I S C K V S G Y <u>A</u> F T	
DP-3	E V Q L V Q S G A E V K K P G A T V K I S C K V S G Y T F T	
		60
PAR34	N Y N M Y W V K Q S H G K S L E W I G <u>Y I D P Y Y G D P G Y</u>	
HuPAR34	N Y N M Y W V <u>R</u> Q A P G K G L E W <u>I</u> G <u>Y I D P Y Y G D P G Y</u>	
DP-3	- - - - - W V Q Q A P G K G L E W M G - - - - -	
		90
PAR34	<u>S Q K F K G</u> K A T L T V D K S S S T A Y M H L N S L T S E D	
HuPAR34	<u>S Q K F K G</u> <u>K A</u> T <u>L</u> T <u>V</u> D <u>K</u> S T <u>S</u> T A Y M E L S S L R S E D	
DP-3	- - - - - R V T I T A D T S T D T A Y M E L S S L R S E D	
		119
PAR34	S A V Y Y C A R <u>R G N F P Y Y F D Y</u> W G Q G T T L T V S S	
HuPAR34	T A V Y Y C A <u>R R G N F P Y Y F D Y</u> W G Q G T L V T V S S	
DP-3/JH4	T A V Y Y C A T - - - - - W G Q G T L V T V S S	

FIG. 10

Alignment of the VL region amino acid sequences of PAR34 (SEQ ID NO:3), HuPAR34 (SEQ ID NO:14), and the human germline L1 and JK4 segments (SEQ ID NO:15).

PAR34	D I K M T Q S P S S M Y A S L G E R V T I T C	<u>K A S Q D I N</u>	30
HuPAR34	D I Q M T Q S P S S L S A S V G D R V T I T C	<u>K A S Q D I N</u>	
L1	D I Q M T Q S P S S L S A S V G D R V T I T C	- - - - -	
PAR34	<u>S Y L S</u> W F Q Q K P G K S P K T L I Y	<u>R A N R L V D</u> G V P S	60
HuPAR34	<u>S Y L S</u> W F Q Q K P G K A P K <u>T L I Y</u>	<u>R A N R L V D</u> G V P S	
L1	- - - - W F Q Q K P G K A P K S L I Y	- - - - - G V P S	
PAR34	R F S G S G S G Q D Y S L T I S S L E Y E D M G I Y Y C	<u>L Q</u>	90
HuPAR34	R F S G S G S G <u>Q D Y</u> T L T I S S L Q P E D F A T Y Y C	<u>L Q</u>	
L1	R F S G S G S G T D F T L T I S S L Q P E D F A T Y Y C	- -	
PAR34	<u>Y D E F P Y T</u> F G G G T K L E I K		107
HuPAR34	<u>Y D E F P Y T</u> F G G G T K V E I K		
Jk4	- - - - - F G G G T K V E I K		

FIG. 11

Nucleotide sequence (SEQ ID NO:16) and deduced amino acid sequence (SEQ ID NO:17) of the heavy chain variable region (including the signal peptide sequence) of HuPAR34 in the mini exon.

```

                                     30                                     60
ACGCGTCCACCATGGAATGGAGATGGATCTTTCTCTTCCTCCTGTCAGGAACTACAGGTG
      M E W R W I F L F L L S G T T G

                                     90                                     120
TCCACTCTGAGGTCCAGCTGGTGCAGTCTGGAGCTGAGGTGAAGAAGCCTGGGGCTTCTG
V H S E V Q L V Q S G A E V K K P G A S

                                     150                                     180
TGAAAATATCCTGCAAGGTTTCTGGTTATGCATTCACTAACTACAACATGTATTGGGTGA
V K I S C K V S G Y A F T N Y N M Y W V

                                     210                                     240
GGCAGGCCCTTGAAAGGGCCTTGAGTGGATTGGATATATTGATCCTTACTATGGTGATC
R Q A P G K G L E W I G Y I D P Y Y G D

                                     270                                     300
CTGGCTACAGCCAGAAGTTCAAGGGCAAGGCCACATTGACTGTTGACAAGTCCACCAGCA
P G Y S Q K F K G K A T L T V D K S T S

                                     330                                     360
CAGCCTACATGGAGCTCAGCAGCCTGAGGTCTGAGGACACTGCAGTCTATTACTGTGCAA
T A Y M E L S S L R S E D T A V Y Y C A

                                     390                                     420
GACGTGGCAACTTCCCGTACTACTTTGACTACTGGGGCCAAGGCACCCTTGTCACAGTCT
R R G N F P Y Y F D Y W G Q G T L V T V

                                     448
CATCAGGTGAGTCCTCACAACCTCTAGA
S S
```

FIG. 12

Nucleotide sequence (SEQ ID NO:18) and deduced amino acid sequence (SEQ ID NO:19) of the light chain variable region (including the signal peptide sequence) of HuPAR34 in the mini exon.

```

                                     30                               60
ACGCGTCCACCATGAGGACCCCTGCTCAGTTTCTTGGTATCTTGTGCTCTGGTTTCCTG
      M R T P A Q F L G I L L L W F P

                                     90                               120
GTATCAAATGTGACATCCAGATGACCCAGTCTCCATCTTCCCTGTCTGCATCTGTTGGAG
G I K C D I Q M T Q S P S S L S A S V G

                                     150                               180
ACAGGGTCACTATCACTTGCAAAGCAAGTCAGGACATTAATAGCTATTTAAGCTGGTTCC
D R V T I T C K A S Q D I N S Y L S W F

                                     210                               240
AGCAGAAACCAGGGAAAGCTCCTAAGACCCTGATCTATCGTGCAAACAGATTGGTAGATG
Q Q K P G K A P K T L I Y R A N R L V D

                                     270                               300
GGGTCCCATCAAGATTCACTGGCAGTGGATCTGGGCAAGATTATACTCTCACCATCAGTA
G V P S R F S G S G S G Q D Y T L T I S

                                     330                               360
GCCTGCAGCCTGAGGATTTGCAACTTATTATTGTCTACAGTATGATGAGTTTCCGTACA
S L Q P E D F A T Y Y C L Q Y D E F P Y

                                     390                               415
CGTTCGGAGGAGGGACCAAGGTGGAAATAAAACGTAAGTGCACTTTCCTTCTAGA
T F G G G T K V E I K
```

FIG. 13




FIG. 14

Oligonucleotide primers used for the synthesis of the HuPAR34 VH gene.

Oligonucleotide 1 (SEQ ID NO:20)

5'-CTAGCCACGCGTCCACCATGGAATGGAGATGGATCTTTCTCTTCCTCCTGTCAGGAACACAGGTGTCCACTCTG-3'

Oligonucleotide 2 (SEQ ID NO:21)

5'-TTCACAGAAGCCCCAGGCTTCTTCACCTCAGCTCCAGACTGCACCAGCTGGACCTCAGAGTGGACACCTGTAGTTCC-3'

Oligonucleotide 3 (SEQ ID NO:22)

5'-AAGCCTGGGGCTTCTGTGAAAATATCCTGCAAGGTTTCTGGTTATGCATTCACTAACTACAACATGTATTGGGTG-3'

Oligonucleotide 4 (SEQ ID NO:23)

5'-CCATAGTAAGGATCAATATATCCAATCCACTCAAGGCCCTTTCCAGGGGCCTGCCTCACCCAATACATGTTGTAGTTAG-3'

Oligonucleotide 5 (SEQ ID NO:24)

5'-GGATATATTGATCCTTACTATGGTGATCCTGGCTACAGCCAGAAGTTCAAGGGCAAGGCCACATTGAC-3'

Oligonucleotide 6 (SEQ ID NO:25)

5'-TGTCTCAGACCTCAGGCTGCTGAGCTCCATGTAGGCTGTGCTGGTGGACTTGTCAACAGTCAATGTGGCCTTGCCCTTG-3'

Oligonucleotide 7 (SEQ ID NO:26)

5'-GCAGCCTGAGGTCTGAGGACACTGCAGTCTATTACTGTGCAAGACGTGGCAACTTCCCGTACTACTTTGACTACTGGGG-3'

Oligonucleotide 8 (SEQ ID NO:27)

5'-GACTCGTCTAGAGGTTGTGAGGACTCACCTGATGAGACTGTGACAAGGTGCCTTGGCCCCAGTAGTCAAAGTAGTACG-3'

Oligonucleotide 9 (SEQ ID NO:28)

5'-CTAGCCACGCGTCCACCATG-3'

Oligonucleotide 10 (SEQ ID NO:29)

5'-GACTCGTCTAGAGGTTGTGAG-3'

FIG. 15

Oligonucleotide primers used for the synthesis of the HuPAR34 VL gene.

Oligonucleotide 1 (SEQ ID NO:30)

5'-CTAGCCACGCGTCCACCATGAGGACCCCTGCTCAGTTTCTTGGTATCTTGTGCTCTGGTTTCCTGGTATC-3'

Oligonucleotide 2 (SEQ ID NO:31)

5'-CAACAGATGCAGACAGGGAAGATGGAGACTGGGTTCATCTGGATGTCACATTGATACCAGGAAACCAGAGCAAC-3'

Oligonucleotide 3 (SEQ ID NO:32)

5'-CTTCCCTGTCTGCATCTGTTGGAGACAGGGTCACTATCACTTGCAAAGCAAGTCAGGACATTAATAGC-3'

Oligonucleotide 4 (SEQ ID NO:33)

5'-GATCAGGGTCTTAGGAGCTTCCCTGGTTTCTGCTGGAACCAGCTTAAATAGCTATTAATGTCCTGACTTGC-3'

Oligonucleotide 5 (SEQ ID NO:34)

5'-GAAAGCTCCTAAGACCCTGATCTATCGTGCAAACAGATTGGTAGATGGGGTCCCATCAAGATTCAGTGGCAGTGGATC-3'

Oligonucleotide 6 (SEQ ID NO:35)

5'-CCTCAGGCTGCAGGCTACTGATGGTGAGAGTATAATCTTGCCCAGATCCACTGCCACTGAATCTTG-3'

Oligonucleotide 7 (SEQ ID NO:36)

5'-CAGTAGCCTGCAGCCTGAGGATTCGCAACTTATTATTGTCTACAGTATGATGAGTTTCCGTACACGTTCGGAGG-3'

Oligonucleotide 8 (SEQ ID NO:37)

5'-GACTCGTCTAGAAGGAAAGTGCACTTACGTTTTATTTCACCTTGGTCCCTCCTCCGAACGTGTACGGAAC-3'

Oligonucleotide 9 (SEQ ID NO:38)

5'-CTAGCCACGCGTCCACCATG-3'

Oligonucleotide 10 (SEQ ID NO:39)

5'-GACTCGTCTAGAAGGAAAG-3'

FIG. 16




FIG. 17

Binding of Biotinylated MuPAR34 to Amphiregulin





FIG. 18



$IC_{50}(\mu g/ml)^*$	
■ HuPAR34	0.055
● PAR34	0.025
□ Humanized IgG1control	
○ MurineIgG2b control	
▼ Media Control	
▲ Mab225	

FIG. 19

HUMAN PSORIATIC SKIN/SCID MOUSE TRANSPLANT MODEL
EFFECT OF HuPAR34 ON NORMAL SKIN GRAFT




FIG. 20

**HUMAN PSORIATIC SKIN/SCID
MOUSE TRANSPLANT MODEL
EFFECT OF HuPAR34 ON PSORIATIC GRAFT**





FIG. 21

Cell Counts - Keratinocytes




Control:KBM

Ab A: Control Antibody


Ab B: anti-amphiregulin antibody

FIG. 22

Cell Counts - Fibroblasts



Procollagen production - Fibroblasts



Control: KBM
Ab A: Control Antibody
Ab B: anti-amphiregulin antibody

FIG. 23